This statement outlines the key findings from the 2014 AACE/ACE Consensus Conference on Obesity.
This statement outlines AACE's position regarding obesity as a disease with multiple pathophysiological aspects, including genetic, environmental, physiological, and psychological factors. It sets the framework for future efforts to advance its treatment and prevention.
Few topics in medicine are more controversial than the use of alternative care methods including dietary supplements and nutraceuticals. Because endocrinologists frequently encounter issues involving DS/N, the information in this report should be helpful.
The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) have created a chronic care model, advanced diagnos-tic framework, clinical practice guidelines, and clinical practice algorithm for the comprehensive management of obesity.
The discipline of clinical nutrition is spread over a diverse array of medical and surgical specialties. Many medical societies report both a significant decrease in and an inadequate number of physician members trained in nutrition at a time when the prevalence of many nutrition-related medical conditions is escalating (1,2).
Epidemiologic data have demonstrated significant increases of various cancers in people with obesity and dia-betes. Recently, concern has emerged that antihyperglyce-mic medications may also be associated with an increased prevalence of multiple cancers; however, available data are limited and conflicting.
Among the more than 20 million Americans whohave diabetes, approximately 30% of the cases are undi-agnosed (1). An additional 42 million people in the UnitedStates have pre-diabetes (impaired glucose tolerance[IGT], impaired fasting glucose, or both), a condition thatoften leads to diabetes if it is not treated (1).
A position statement by the American Association of Clinical Endocrinologists
Recent reports of diabetic ketoacidosis (DKA) occur-ring in conjunction with sodium glucose-cotransporter 2 (SGLT-2) inhibitor therapy have raised concerns that these agents may increase the risk of DKA, especially among patients taking exogenous insulin. On May 15, 2015, the U.S.
Lipodystrophy is a rare, heterogeneous group of syndromes characterized by the complete or partial loss or absence of subcutaneous adipose tissue (1,2).
Evidence-based medicine has generated many philosophical and pragmatic challenges to clinical care. Chief among these challenges is how to deliver culturally appropriate individualized endocrine care while adhering to evidence-based guidelines and algorithms developed for large heterogeneous populations.
Since its inception, the American Association of Clinical Endocrinologists (AACE) has advocated for the finest in endocrine education and state-of-the-art health-care delivery without regard to race, ethnicity, gender, age, country of origin, economic status, lifestyle, sexual orientation or domestic living arrangements.
Several recent publications have raised concern that testosterone therapy in men increases cardiovascular risks. Media reports declared that testosterone therapy is dangerous, without addressing the scientific validity of these studies.
The most recent American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) clinical practice guidelines for the treatment of menopause was published in 2011 (1).
The desire to maintain health, including bone health, into old age has led to almost one-half of the population and 70% of older adults in the United States and up to 26% in Europe using dietary supplements. Dietary supplements allow for randomized controlled trials (RCTs) that can assess a single nutrient.
Angelo A. Licata, Neil Binkley, Steven M. Petak and Pauline M. Camacho
Feb 2018, Vol. 24, No. 2 (February 2018) pp. 220-229